Buspirone for Early Satiety and Symptoms of Gastroparesis
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This study evaluates whether the study medication, buspirone, an antianxiety drug, improves
the symptoms of gastroparesis in patients with gastroparesis symptoms and at least moderately
severe symptoms of fullness and/or inability to eat a full meal. Half the patients will
receive buspirone and half the patients will receive a placebo.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)